Si Chuan Venture Capital

Si Chuan Venture Capital is a fund management and investment firm that focuses on providing financial support to promising businesses and startups. With a strong emphasis on strategic investments, the company plays a crucial role in fostering innovation and growth within the market. Through careful analysis and meticulous planning, Si Chuan Venture Capital aims to generate long-term value for both its investors and the companies it supports. By leveraging its expertise and resources, the firm actively contributes to the success and development of emerging enterprises, ultimately seeking to create a prosperous and sustainable business ecosystem.

Zhang Fan

Investment Director

19 past transactions

RootPath Genomics

Venture Round in 2025
RootPath Genomics, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2017. It specializes in developing a personalized T-cell therapy platform that integrates precision medicine with cancer immunotherapy. The company's innovative technologies focus on the analysis and manipulation of individual immune cells, enabling advancements in immune and cell therapy. By precisely monitoring and modulating the immune system, RootPath aims to enhance the diagnosis and treatment of cancer, contributing to significant improvements in patient outcomes.

Geneus

Series B in 2025
Geneus develops and commercializes gene sequencers and reagents. The core of its technology is based on the characteristic current signal generated by the interaction of protein nanopores and nucleic acid bases, and it realizes single-molecule nucleic acid sequencing through an integrated chip system.

Gene Vector

Venture Round in 2025
Chengdu Genevector Biotechnology Co., Ltd. is a biotechnology company specializing in the research and development of adeno-associated virus (AAV) gene therapy drugs. The company is dedicated to creating innovative therapeutics aimed at treating ophthalmic diseases, neuromuscular disorders, and various genetic and metabolic conditions. By focusing on gene therapy for significant health issues, including hereditary, cardiovascular, cerebrovascular, and neurodegenerative diseases, Genevector aims to establish a comprehensive technology chain for AAV drug development, ultimately delivering advanced biotherapy solutions to the medical field.

New Radiomedicine Technology

Series C in 2024
Chengdu New Radiomedicine Technology Co.,Ltd. is a Chinese medical isotopes provider. Our business covers research, manufacture and sales for medical isotopes and products. We provide services for malignant tumor diagnosis and treatments and radionuclides medicine technology support and consulting. In April 2016, the company was founded by three co-founders experienced in radionuclides research and development. Jihui Qian, former President of Nuclear Power Institute of China (NPIC), former Deputy Director-General of International Atomic Energy Agency (IAEA); Maoliang Li, former Director of Chengdu Isotopes Institute of NPIC; and Jiming Cai, former Vice President of Sichuan Institute of Atomic Energy. The company is located in Western Airport Development District, Shuangliu, Chengdu, with an area of 71 Are, registered capital of 32.83 million CNY, and total investment of 300 million CNY. The project is listed as "Annual Key Investment Projects of Sichuan Province and Chengdu City in 2017, 2018 and 2019". At present, the company has over 80 employees, with more than 60 R&D specialists, including 1 academician of Chinese Academy of Engineering, 2 experts of Thousand Talent Project, 2 academic and technical leaders from Sichuan province, 10 researchers (associate researchers), and more than 20 people with middle or senior titles. Among them, there are 6 PhDs and over 30 graduates. The proportion of R&D staff has reached 70%, making CNRT the most innovative technology enterprise in the radiopharmaceutical industry in China.

Baoling Bio

Series B in 2023
Baoling Bio is an innovative drug research and development and industrialization service provider. The company's research and development pipeline covers the research and development of innovative drugs such as tumors (solid tumors and hematomas), autoimmune diseases, and cytokine storms caused by new coronavirus pneumonia.

Gachun Biotech

Series A in 2023
Gachun Biotech is a pharmaceutical intermediates industrialization platform that focuses on APIs, or pharmaceutical intermediates.

Fibresound Technology

Seed Round in 2023
Fibresound Technology is a chip development company that specializes in the R&D and design of piezoelectric MEMS microphone chips.

Illumax

Series A in 2023
Illumax is a company that specialises in the research and development of single-serve chemiluminescence, single-serve flow fluorescence, and laboratory automation technologies. It also offers the industry an open ecological platform for chemiluminescence and flow fluorescence.

RiVAI

Venture Round in 2023
RiVAI Technologies specializes in the development of advanced RISC-V based CPUs and customized System-on-Chip (SoC) designs. The company focuses on delivering high-performance computing solutions for diverse applications, ranging from edge computing to data centers. Additionally, RiVAI develops artificial intelligence chips tailored for Internet of Things (IoT) applications, catering to various sectors such as wearable technology, smart homes, security systems, agriculture, and consumer electronics. By offering low-power yet high-performance core processor chips, RiVAI enables its clients to meet the growing demands of modern computing environments.

Baoling Bio

Series A in 2021
Baoling Bio is an innovative drug research and development and industrialization service provider. The company's research and development pipeline covers the research and development of innovative drugs such as tumors (solid tumors and hematomas), autoimmune diseases, and cytokine storms caused by new coronavirus pneumonia.

Ghostcloud

Series B in 2019
Ghostcloud, based in Chengdu Tianfu Software Park, is a prominent enterprise specializing in container virtualization and hybrid cloud solutions. The company develops a Docker-based platform that assists enterprises in integrating Docker into their operations. Ghostcloud offers a range of services, including cloud computing infrastructure, platform-as-a-service, and container-as-a-service solutions, tailored for private and hybrid cloud environments. By leveraging its expertise in big data and cloud management, Ghostcloud enables businesses to reduce hardware costs, enhance operational efficiency, streamline maintenance, accelerate product development, and bolster system security. As a key player in the Chengdu Hi-tech Zone, Ghostcloud is committed to advancing cloud technology for various industries.

Jinglingyun Xiao

Series A in 2019
Jinglingyun Xiao builds a SaaS cloud platform for education and training institutions.

Hyperway Pharm

Angel Round in 2019
Hyperway Pharm is a pharmaceutical research and development enterprise specializing in the development and production of small-molecule drugs aimed at treating various diseases. The company is dedicated to establishing a world-class research and development platform, emphasizing innovation in small molecule drugs and high-end active pharmaceutical ingredients (APIs). Its core team, comprised of high-end talent from Chengdu, Sichuan Province, boasts extensive experience with prominent Fortune 500 companies and well-known domestic pharmaceutical firms. This expertise allows Hyperway Pharm to navigate the complexities of drug development effectively. The company has successfully developed several innovative drugs that are currently in clinical trials, alongside a range of high-quality generic drugs, ensuring a commitment to safety and efficacy in its offerings.

Stork Healthcare

Series A in 2019
Stork Healthcare is a company focused on portable, non-invasive diagnostic ultrasound medical equipment and services. It develops handheld ultrasound scanning technology that provides instant, analysis-ready images, enhancing the capability of healthcare professionals to deliver effective treatment. The company features its own original imaging platform and offers several advanced technologies, including elastic imaging technology and 3D Doppler spectrum imaging. Stork Healthcare's product line includes handheld ultrasound devices designed for diagnosing liver disease, conducting cervical vascular screenings, and screening for thyroid conditions.

EVspeak

Series A in 2019
EVspeak is a new energy vehicle intelligent networked software and hardware integrated solution provider. Based on vehicle intelligent hardware and cloud multi-source heterogeneous big data cloud control platform, it provides customers with car road cloud collaborative unmanned driving. A number of new energy vehicle intelligent network services and related products, including vehicle life cycle management, intelligent networked software and hardware solutions, and new energy vehicle electronic control system development.

Alinket

Series D in 2018
Alinket is a technology company that provides integrated solutions for the internet of things, including IoT controllers, IoT middleware, cloud access technology, and comprehensive application technology. It also offers sensor kits, audio kits, health kits, sports kits, and medical kits.

Shanghai Monolith Technology Co.,Ltd

Series A in 2017
Shanghai Monolith Technology Co.,Ltd provides intelligent manufacturing system solutions to logistics and manufacturing sectors.

Oriented Knowledge

Series A in 2017
Oriented Knowledge is an AI-based education service provider.

Sichuan Jiuzhou Beidou Daohang Yuweizhi Fuwu Co.

Series A in 2015
Sichuan Jiuzhou Beidou Daohang Yuweizhi Fuwu is a provider of automobile navigation and location services. They serve the electronic information industry, mainly providing military information, equipment, and systems, as well as military industrial fusion digital intelligence software and hardware products and services.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.